LAB150 adds project with focus on mental health
Toronto, ON, June 11, 2019 (GLOBE NEWSWIRE) -- It is estimated that 5% of the global population is affected by Major Depressive Disorder (MDD) at any given time. While there…
Triphase Accelerator Enters Partnership with Celgene for Leukemia Therapy
Toronto, ON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Triphase Accelerator, a Toronto-based drug development company, has entered into a new strategic partnership with Celgene Corporation. The focus of the collaboration…
LAB150 adds two projects: Cystic Fibrosis and Respiratory Syncytial Virus
Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by…
Fibrocor Therapeutics enters deal with Galapagos NV
Toronto, ON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fibrocor Therapeutics, a privately held Canadian company, and Galapagos NV, a Belgo-Dutch pharmaceutical research company, have announced the formation of a partnership…
IP Protection for Antibody-based Assets in the Canadian Market and beyond
Together with Noel Courage, MI's Philip Goldbach co-authored an article published in BioTechnology Focus on IP rights and considerations surrounding antibody-based assets. As the article states: Antibodies (immunoglobulins) and other antibody-derived…
MI Leads Special Health Innovation & Investment Mission to Seoul
Toronto, April 13, 2018 (GLOBE NEWSWIRE) -- Dr. Rafi Hofstein, President and CEO of MaRS Innovation (MI) announced today that as part of Toronto Health Innovation Week, MI will lead…
2017 Year in Review
MaRS Innovation looks back at the year that was: a summary of the main events of the past 12 months, including creation of LAB150, collaboration with strategic partners and significant…
Zucara raises US$3.9M Funding to advance drug for hypoglycemia prevention
Toronto and Vancouver, Canada: Zucara Therapeutics Inc., a diabetes life sciences company advancing the first once-daily therapeutic to prevent low blood glucose levels (hypoglycemia), has secured US$3.9 million in non-dilutive funding…
$800,000 MaRS Innovation–Pfizer Translational Research Fund
KIRKLAND, Quebec and TORONTO, April 09, 2018 (GLOBE NEWSWIRE) -- Pfizer Canada is proud to announce an $800,000 contribution to MaRS Innovation to support the vision and mission of MaRS…
FIRST FUNDED PROJECT UNDER LAB150 BRIDGE ANNOUNCED!
Hamburg, Germany, and Toronto, Canada, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and MaRS Innovation announced today that they have identified the…